Susquehanna International Group, LLP Nymox Pharmaceutical Corp Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 16, 2020	SELL	$2.3 - $3.66 $105,339 - $167,628	-45,800 Reduced 73.99%	16,100 $40,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $4.6 $103,740 - $227,239	49,400 Added 395.2%	61,900 $220,000
Q3 2019 Nov 14, 2019	SELL	$1.41 - $2.12 $7,050 - $10,600	-5,000 Reduced 28.57%	12,500 $23,000
Q2 2019 Aug 14, 2019	BUY	$1.33 - $2.12 $2,793 - $4,452	2,100 Added 13.64%	17,500 $25,000
Q4 2018 Feb 14, 2019	SELL	$1.31 - $2.53 $39,562 - $76,406	-30,200 Reduced 66.23%	15,400 $20,000
Q2 2018 Aug 14, 2018	BUY	$3.12 - $4.33 $48,984 - $67,981	15,700 Added 52.51%	45,600 $153,000
Q1 2018 May 15, 2018	BUY	$3.09 - $4.43 $92,391 - $132,457	29,900 New	29,900 $126,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.